Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

@article{Kantarjian2007ResultsOA,
  title={Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.},
  author={Hagop M Kantarjian and Yasuhiro Oki and Guillermo Garcia-Manero and Xuelin Huang and Sallyann O'Brien and Jorge E Cortes and Stefan Faderl and Carlos E Bueso-Ramos and Farhad Ravandi and Zeev Estrov and Alessandra Ferrajoli and William G Wierda and Jianqin Shan and Jan R Davis and F. R. Giles and Hussain I. Saba and Jean-Pierre Issa},
  journal={Blood},
  year={2007},
  volume={109 1},
  pages={52-7}
}
Epigenetic therapy with hypomethylating drugs is now the standard of care in myelodysplastic syndrome (MDS). Response rates remain low, and mechanism-based dose optimization has not been reported. We investigated the clinical and pharmacodynamic results of different dose schedules of decitabine. Adults with advanced MDS or chronic myelomonocytic leukemia (CMML) were randomized to 1 of 3 decitabine schedules: (1) 20 mg/m2 intravenously daily for 5 days; (2) 20 mg/m2 subcutaneously daily for 5… CONTINUE READING
Highly Influential
This paper has highly influenced 18 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
210 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 210 extracted citations

Similar Papers

Loading similar papers…